In medical school, I remember being fascinated about the trade-offs that may arise when a genetic susceptibility to one disease possibly reduces the risk of another.

The example provided was how the heterozygous (unaffected) carrier of sickle cell disease, with one mutated allele, is protected against severe episodes of malaria and thus has a survival advantage in endemic areas.